The market capitalization for Merck & Co., Inc. (MRK) is $293.02 Billion, making it a Large Cap company. Market cap is calculated by multiplying the current stock price by the total number of shares outstanding.
Market Capitalization
$293.02B
$293.02 Billion
Calculation
- Stock Price
- $118.47
- Shares Outstanding
- 2.47B
- Market Cap
- $293.02B
Market Cap = Price × Shares Outstanding
Size Classification
Large Cap
$10B - $1T
Companies with market capitalization between $10 billion and $1 trillion.
Market Cap Size Scale
Micro Cap
<$250M
Small Cap
$250M-$2B
Mid Cap
$2B-$10B
Large Cap
$10B-$1T
Mega Cap
>$1T
Related Valuation Metrics
Key Statistics
| Market Cap | $293.02 Billion |
| Stock Price | $118.47 |
| Shares Outstanding | 2.47B |
| Size Category | Large Cap |
| P/E Ratio | 33.37 |
| P/B Ratio | 6.38 |
About Merck & Co., Inc.
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert Davis